Tag: Cancer: Lung
ASCO: PD-1 Immunotherapy Benefits Patients With NSCLC
Fewer side effects, longer survival for nivolumab versus docetaxel
Statins Linked to Improved Survival in Lung Cancer
But more research needed
Two New Lung Cancer Meds Show Promise in Advanced Disease
Two experimental medications target mutation that fuels treatment resistance
Gene Variation May Impact Smoking Cessation Efforts
Researcher suggests a change in screening policies
AACR: Pembrolizumab Shows Promise in Advanced Lung Cancer
Keytruda (pembrolizumab) is already approved to treat melanoma
Pulmonologist Management Beneficial in NSCLC
Improved rates of stage-specific treatment for early-, advanced-stage NSCLC with comorbid COPD
Most Cancer Patients Involve Family in Treatment Decisions
Chinese-speaking Asians, Spanish-speaking Hispanics more often share decisions with family
FDA: Opdivo Approval Expanded to Include Lung Cancer
FDA approves drug for NSCLC patients who have been treated with platinum-based chemotherapy
L858R Mutation in Circulating Free DNA Is Prognostic in NSCLC
L858R mutation in tumor tissue or cfDNA is marker of shorter overall, progression-free survival
Lung-RADS Criteria Can Reduce False-Positive Result Rate
Reduction in false-positive result rate, but reduction in sensitivity also observed
